NOVN

Novan (NOVN)

Novan Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:NOVN

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/02	13:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:NOVN	Novan Inc
2024/05/02	13:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:NOVN	Novan Inc
2024/05/02	13:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:NOVN	Novan Inc
2024/05/02	00:49	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:NOVN	Novan Inc
2024/05/02	00:48	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:NOVN	Novan Inc
2024/05/02	00:44	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:NOVN	Novan Inc
2024/05/02	00:41	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:NOVN	Novan Inc
2024/05/02	00:37	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:NOVN	Novan Inc
2024/03/25	21:54	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
2024/02/27	06:22	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
2024/01/31	06:47	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
2024/01/27	06:38	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
2024/01/05	23:23	GlobeNewswire Inc.	Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis	NASDAQ:NOVN	Novan Inc
2023/12/22	06:13	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
2023/12/11	09:30	GlobeNewswire Inc.	Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)	NASDAQ:NOVN	Novan Inc
2023/12/08	23:15	GlobeNewswire Inc.	Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions	NASDAQ:NOVN	Novan Inc
2023/12/06	09:16	GlobeNewswire Inc.	Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH	NASDAQ:NOVN	Novan Inc
2023/11/20	15:15	GlobeNewswire Inc.	Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH	NASDAQ:NOVN	Novan Inc
2023/10/25	06:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
2023/10/21	06:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
2023/09/08	05:58	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
2023/08/25	05:31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
2023/07/27	05:50	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
2023/07/18	05:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
2023/07/17	22:23	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
2023/07/17	21:45	GlobeNewswire Inc.	Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection	NASDAQ:NOVN	Novan Inc
2023/07/07	06:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
2023/06/28	07:30	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:NOVN	Novan Inc
2023/06/17	06:02	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:NOVN	Novan Inc
2023/06/12	22:06	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:NOVN	Novan Inc